OralTherapeutic flag
Tamoxifen
CAS 10540-29-1
Tamoxifen (CAS 10540-29-1) is a Phase 4 pharmaceutical compound with 65 bioactivity targets and 1,598 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
77
SOURCE
DrugCentral
Adverse signals
1,598
SOURCE
IUPHAR/BPS
PubMed IDs
32
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Tamoxifen
CAS Number
10540-29-1
UNII
094ZI81Y45
InChIKey
NKANXQFJJICGDU-QPLCGJKRSA-N
ChEMBL ID
CHEMBL83
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Tamoxifen Citrate
black box warningoraltherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL83 | Small molecule
SOURCE
EMBL-EBI ChEMBL
77 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 14827.782802850355 nM | 420 | - |
| - | AC50 | 18384.081714285716 nM | 105 | - |
| - | GI50 | 8070.906190476191 nM | 63 | - |
| - | Potency | 25652.495402298853 nM | 60 | - |
| - | Ki | 4102.770931034483 nM | 58 | - |
| - | EC50 | 19281.505 nM | 22 | - |
| - | IC50 | 6.5175 ug.mL-1 | 16 | - |
| - | MIC | 38.18181818181818 ug.mL-1 | 11 | - |
| - | GI50 | 10 ug.mL-1 | 1 | - |
| - | Kd | 1 nM | 1 | - |
| Adenosine receptor A1 GPCR |
Ki | 4.858 | - | Homo sapiens |
| Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel |
IC50 | 4.807 | - | Sus scrofa |
| Beta-1 adrenergic receptor GPCR |
Ki | 5.001 | - | Homo sapiens |
| Prostaglandin G/H synthase 2 Enzyme |
IC50 | 4.46 | - | Homo sapiens |
| Prostaglandin G/H synthase 1 Enzyme |
IC50 | 5.357 | - | Homo sapiens |
| Mu-type opioid receptor GPCR |
Ki | 5.146 | - | Homo sapiens |
| D(1A) dopamine receptor GPCR |
Ki | 5.372 | - | Homo sapiens |
| D(2) dopamine receptor GPCR |
Ki | 5.335 | - | Homo sapiens |
| Adenosine receptor A2a GPCR |
Ki | 5.4 | - | Homo sapiens |
| Alpha-2A adrenergic receptor GPCR |
Ki | 6.139 | - | Homo sapiens |
| Sigma non-opioid intracellular receptor 1 Membrane receptor |
Ki | 7.5 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily H member 2 Ion channel |
IC50 | 5.8 | - | Homo sapiens |
| 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Enzyme |
Ki | 8.301 | - | Homo sapiens |
| Multidrug resistance protein 1 Transporter |
Ki | 7 | - | Homo sapiens |
| Sodium-dependent serotonin transporter Transporter |
Ki | 5.907 | - | Homo sapiens |
| Sodium-dependent noradrenaline transporter Transporter |
Ki | 5.836 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 1A GPCR |
Ki | 5.158 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2A GPCR |
Ki | 5.863 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2B GPCR |
Ki | 5.877 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 2C GPCR |
Ki | 6.618 | - | Homo sapiens |
| 5-hydroxytryptamine receptor 6 GPCR |
Ki | 5.98 | - | Homo sapiens |
| Alpha-2B adrenergic receptor GPCR |
Ki | 5.794 | - | Homo sapiens |
| D(3) dopamine receptor GPCR |
Ki | 6.439 | - | Homo sapiens |
| Histamine H2 receptor GPCR |
Ki | 5.034 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M1 GPCR |
Ki | 6.167 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M2 GPCR |
Ki | 5.557 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M3 GPCR |
Ki | 6.201 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M4 GPCR |
Ki | 6.173 | - | Homo sapiens |
| Muscarinic acetylcholine receptor M5 GPCR |
Ki | 5.731 | - | Homo sapiens |
| Aldehyde oxidase Enzyme |
IC50 | 5.658 | - | Homo sapiens |
| Beta-3 adrenergic receptor GPCR |
Ki | 5.238 | - | Homo sapiens |
| Sodium-dependent dopamine transporter Transporter |
Ki | 5.835 | - | Homo sapiens |
| Adenosine receptor A3 GPCR |
Ki | 5.679 | - | Homo sapiens |
| Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor |
Ki | 7.456 | - | Homo sapiens |
| D(4) dopamine receptor GPCR |
Ki | 5.407 | - | Homo sapiens |
| Alpha-1D adrenergic receptor GPCR |
Ki | 5.611 | - | Homo sapiens |
| Kappa-type opioid receptor GPCR |
Ki | 5.204 | - | Homo sapiens |
| Estrogen receptor Nuclear hormone receptor |
Ki | 7.51 | - | Homo sapiens |
| Progesterone receptor Nuclear hormone receptor |
IC50 | 6.89 | - | Homo sapiens |
| Delta-type opioid receptor GPCR |
Ki | 5.328 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Metastases to bone | 753 | 2218.542 | 10027452 |
| Malignant neoplasm progression | 1053 | 1784.654 | 10051398 |
| Metastases to liver | 495 | 1194.816 | 10027457 |
| Metastases to lung | 311 | 760.029 | 10027458 |
| Breast cancer recurrent | 183 | 636.496 | 10006198 |
| Metastases to lymph nodes | 225 | 597.144 | 10027459 |
| Breast cancer metastatic | 217 | 586.99 | 10055113 |
| Disease progression | 548 | 432.1 | 10061818 |
| Neoplasm progression | 289 | 420.169 | 10061309 |
| Breast cancer | 254 | 387.542 | 10006187 |
| Osteonecrosis of jaw | 208 | 268.244 | 10064658 |
| Metastases to central nervous system | 150 | 265.721 | 10059282 |
| Metastasis | 116 | 259.581 | 10062194 |
| PIK3CA-activated mutation | 62 | 230.597 | 10081234 |
| Metastases to spine | 88 | 220.463 | 10027468 |
| Hot flush | 194 | 188.818 | 10060800 |
| Tumour marker increased | 76 | 183.863 | 10048621 |
| Uterine polyp | 57 | 178.739 | 10046811 |
| Endometrial hyperplasia | 47 | 175.717 | 10014755 |
| Bone lesion | 81 | 166.055 | 10061728 |
| Metastases to pleura | 53 | 159.248 | 10027463 |
| Bone disorder | 118 | 158.832 | 10005956 |
| Metastases to skin | 53 | 156.255 | 10027465 |
| Carbohydrate antigen 15-3 increased | 45 | 144.234 | 10051415 |
| Osteonecrosis | 125 | 135.474 | 10031264 |
| Metastases to the mediastinum | 38 | 133.136 | 10027469 |
| Hormone receptor positive breast cancer | 34 | 131 | 10083234 |
| Hepatic lesion | 68 | 129.577 | 10061998 |
| Pseudocirrhosis | 35 | 126.042 | 10076501 |
| Metastases to peritoneum | 56 | 119.941 | 10051676 |
| Neuropathy peripheral | 275 | 119.227 | 10029331 |
| Sarcoma uterus | 19 | 113.379 | 10039497 |
| Endometrial hypertrophy | 26 | 109.969 | 10014756 |
| Bone pain | 151 | 106.516 | 10006002 |
| Endometrial cancer | 43 | 105.153 | 10014733 |
| Acute myeloid leukaemia | 106 | 102.343 | 10000880 |
| Second primary malignancy | 77 | 100.864 | 10039801 |
| Contraindicated product administered | 6 | 98.175 | 10078504 |
| Hysteroscopy | 17 | 97.337 | 10050125 |
| Tonsillar disorder | 34 | 95.862 | 10053477 |
| Uterine cancer | 45 | 94.732 | 10046766 |
| Breast mass | 55 | 93.287 | 10006272 |
| Invasive ductal breast carcinoma | 49 | 89.296 | 10073095 |
| Pulmonary mass | 95 | 88.514 | 10056342 |
| Lymphoedema | 67 | 88.373 | 10025282 |
| Device related thrombosis | 37 | 85.325 | 10077455 |
| Nail disorder | 64 | 83.164 | 10028694 |
| Systemic lupus erythematosus | 7 | 81.099 | 10042945 |
| Blood uric acid decreased | 28 | 79.27 | 10005860 |
| Therapeutic product effect decreased | 9 | 79.257 | 10082201 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
7 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Estrogen receptor-α ESR1 |
Agonist | 7.820000171661377 pKi | 9048584 |
| Estrogen receptor-α ESR1 |
Antagonist | 7.800000190734863 pKi | 9048584 |
| Estrogen receptor-β ESR2 |
Agonist | 7.16 pKi | 9048584 |
| Estrogen receptor-β ESR2 |
Antagonist | 7.17 pKi | 9048584 |
| GPER GPER1 |
Full agonist | 6.0 pKi | 15539556 |
| Maxi Cl - | Activator | - | - |
| VRAC | Channel blocker | - | - |
SOURCE
PharmGKB
60 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
CYP2D6 (PA128) CYP2D6 poor metabolizers
CYP2D6 poor metabolizers are not associated with decreased risk of Hot Flashes when treated with tamoxifen as compared to CYP2D6 normal metabolizers.
Evidence: -; PMID 22735900
CYP19A1 (PA27091) rs4646
Genotype AA is associated with decreased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.
Evidence: -; PMID 25793413
CYP19A1 (PA27091) rs4646
Genotype AA is associated with increased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms as compared to genotypes AC + CC.
Evidence: -; PMID 25793413
CYP2C9 (PA126) CYP2C9*1, CYP2C9*2
CYP2C9 *2 is not associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2C9 *1.
Evidence: -; PMID 18024866
CYP2D6 (PA128) rs3892097
Genotype TT is associated with increased disease free survival when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.
Evidence: -; PMID 17244352
CYP2D6 (PA128) rs3892097
Genotype TT is associated with decreased severity of hot flashes when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.
Evidence: -; PMID 16361630
LRMDA (PA134899373) rs10509373
Allele C is associated with decreased recurrence-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to allele T.
Evidence: -; PMID 22180457
CYP2D6 (PA128) CYP2D6*1, CYP2D6*10
CYP2D6 *10/*10 is associated with increased risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*10.
Evidence: -; PMID 18294285
ABCB1 (PA267) rs2032582
Allele C is not associated with increased or decreased recurrence-free survival time when treated with tamoxifen as compared to allele A.
Evidence: -; PMID 20124171
ABCB1 (PA267) rs3213619
Allele A is not associated with increased or decreased recurrence-free survival time when treated with tamoxifen as compared to allele G.
Evidence: -; PMID 20124171
ABCC2 (PA116) rs3740065
Genotype AA is not associated with increased or decreased plasma levels of endoxifen or 4-hydroxytamoxifen in recipients of tamoxifen as compared to genotype GG.
Evidence: -; PMID 20124171
CYP3A5 (PA131) CYP3A5 haplotype
CYP3A5 poor metabolizer and intermediate metabolizer genotypes are not associated with concentrations of tamoxifen in women with Breast Neoplasms.
Evidence: -; PMID 29436156
ESR1 (PA156) rs9340799
Genotype GG is associated with decreased in total cholesterol in postmenopausal woman and increase in triglycerides and decrease in high density lipoprotein in premenopausal women when treated with tamoxifen as compared to genotypes AA + AG.
Evidence: -; PMID 17713466
ESR2 (PA27886) rs4986938
Genotype CC is associated with increased triglycerides in postmenopausal woman when treated with tamoxifen as compared to genotype TT.
Evidence: -; PMID 17713466
CYP2D6 (PA128) rs3892097
Genotype TT is associated with decreased relapse free time when treated with tamoxifen in people with Breast Neoplasms as compared to genotypes CC + CT.
Evidence: -; PMID 16361630
CYP3A (PA27114),"CYP3A5 (PA131)" rs776746
Allele T is not associated with survival when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.
Evidence: -; PMID 16361630
CYP2D6 (PA128) rs1065852
Allele A is associated with increased risk of recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to allele G.
Evidence: -; PMID 18024866
CYP2D6 (PA128) rs3892097
Allele C is associated with increased risk of recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to allele T.
Evidence: -; PMID 18024866
CYP2D6 (PA128) rs28371725
Allele T is associated with increased risk of recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to allele C.
Evidence: -; PMID 18024866
CYP2C19 (PA124) rs12248560
Allele T is associated with decreased risk of Recurrence when treated with tamoxifen in people with Breast Neoplasms as compared to genotype CC.
Evidence: -; PMID 18024866
RRAS2 (PA34862) rs11023197
Allele A is associated with increased frequency of relapse when treated with tamoxifen in people with Breast Neoplasms as compared to allele G.
Evidence: -; PMID 19047159
CYP2C19 (PA124) CYP2C19*1, CYP2C19*2
CYP2C19 *2 is associated with increased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.
Evidence: -; PMID 21830868
CYP2C19 (PA124) CYP2C19*1, CYP2C19*17
CYP2C19 *17 is associated with decreased response to tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.
Evidence: -; PMID 21830868
CYP2D6 (PA128) CYP2D6*1, CYP2D6*4
CYP2D6 *4 is not associated with response to antineoplastic agents and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1.
Evidence: -; PMID 21830868
ESR1 (PA156) rs9340799
Genotype GG is not associated with tamoxifen-induced changes in levels of total cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol when treated with tamoxifen as compared to genotypes AA + AG.
Evidence: -; PMID 20827267
IGF1 (PA29697) rs6214
Allele T is not associated with risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to allele C.
Evidence: -; PMID 23459444
CYP3A4 (PA130) rs2740574
Genotype CT is associated with increased risk of Endometrial Neoplasms when treated with tamoxifen in people with Breast Neoplasms as compared to genotype TT.
Evidence: -; PMID 17434921
IGFBP3 (PA29705) rs2854744
Allele T is not associated with risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to allele G.
Evidence: -; PMID 23459444
IGF1 (PA29697) rs2946834
Allele A is not associated with risk of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to allele G.
Evidence: -; PMID 23459444
CYP2C19 (PA124) CYP2C19*1, CYP2C19*17
CYP2C19 *17 is not associated with increased event-free survival when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2C19 *1.
Evidence: -; PMID 21961651
SOURCE
NLM RxNorm
6 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TAMOXIFEN | 10324 | SU | MTHSPL |
| Tamoxifen | 10324 | SU | MTHSPL |
| Tamoxifen Citrate | 40137 | SU | MTHSPL |
| TAMOXIFEN CITRATE | 40137 | SU | MTHSPL |
| tamoxifen | 10324 | IN | RXNORM |
| tamoxifen citrate | 40137 | PIN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal cramps | tamoxifen | LLT | C0000729 |
| Abdominal discomfort | tamoxifen | PT | C0232487 |
| Abdominal pain | tamoxifen | PT | C0000737 |
| Abdominal pain | tamoxifen | LLT | C0000737 |
| Abdominal pain | tamoxifen | PT | C0000737 |
| Accidental exposure to product | tamoxifen | PT | C3544060 |
| Accidental ingestion | tamoxifen | LLT | C0857807 |
| Accidental injury | tamoxifen | LLT | C0151736 |
| Acute coronary syndrome | tamoxifen | PT | C0948089 |
| Adenocarcinoma | tamoxifen | LLT | C0001418 |
| Adenocarcinoma | tamoxifen | PT | C0001418 |
| Alanine aminotransferase increased | tamoxifen | LLT | C0151905 |
| Alanine aminotransferase increased | tamoxifen | PT | C0151905 |
| Alopecia | tamoxifen | LLT | C0002170 |
| Alopecia | tamoxifen | PT | C0002170 |
| Alopecia | tamoxifen | LLT | C0002170 |
| Alopecia | tamoxifen | PT | C0002170 |
| Amenorrhoea | tamoxifen | LLT | C0002453 |
| Amenorrhoea | tamoxifen | PT | C0002453 |
| Anaemia | tamoxifen | LLT | C0002871 |
| Anaemia | tamoxifen | PT | C0002871 |
| Angina pectoris | tamoxifen | LLT | C0002962 |
| Angina pectoris | tamoxifen | PT | C0002962 |
| Angioedema | tamoxifen | LLT | C0002994 |
| Angioedema | tamoxifen | PT | C0002994 |
| Angioedema | tamoxifen | LLT | C0002994 |
| Angioedema | tamoxifen | PT | C0002994 |
| Ankle edema | tamoxifen | LLT | C0235439 |
| Anorexia | tamoxifen | LLT | C0003123 |
| Anxiety | tamoxifen | LLT | C0003467 |
| Anxiety | tamoxifen | PT | C0003467 |
| Appetite absent | tamoxifen | LLT | C1971624 |
| Arrhythmia | tamoxifen | LLT | C0003811 |
| Arrhythmia | tamoxifen | PT | C0003811 |
| Arthralgia | tamoxifen | LLT | C0003862 |
| Arthralgia | tamoxifen | PT | C0003862 |
| Arthritis | tamoxifen | LLT | C0003864 |
| Arthritis | tamoxifen | PT | C0003864 |
| Arthropathy | tamoxifen | LLT | C0022408 |
| Arthropathy | tamoxifen | PT | C0022408 |
| Aspartate aminotransferase increased | tamoxifen | LLT | C0151904 |
| Aspartate aminotransferase increased | tamoxifen | PT | C0151904 |
| Asthenia | tamoxifen | LLT | C0004093 |
| Asthenia | tamoxifen | PT | C0004093 |
| Asthenia | tamoxifen | PT | C0004093 |
| Back pain | tamoxifen | LLT | C0004604 |
| Back pain | tamoxifen | PT | C0004604 |
| Benign neoplasm | tamoxifen | LLT | C0086692 |
| Benign neoplasm | tamoxifen | PT | C0086692 |
| Blindness | tamoxifen | LLT | C0456909 |
| Blindness | tamoxifen | PT | C0456909 |
| Blindness | tamoxifen | LLT | C0456909 |
| Blindness | tamoxifen | PT | C0456909 |
| Blister | tamoxifen | LLT | C0005758 |
| Blister | tamoxifen | PT | C0005758 |
| Blood bilirubin increased | tamoxifen | LLT | C0311468 |
| Blood bilirubin increased | tamoxifen | PT | C0311468 |
| Blood creatinine increased | tamoxifen | PT | C0235431 |
| Blood triglycerides increased | tamoxifen | PT | C0853692 |
| Bone pain | tamoxifen | LLT | C0151825 |
| Bone pain | tamoxifen | PT | C0151825 |
| Breast cancer male | tamoxifen | LLT | C0238033 |
| Breast cancer male | tamoxifen | PT | C0238033 |
| Breast feeding | tamoxifen | LLT | C0006147 |
| Breast feeding | tamoxifen | PT | C0006147 |
| Breast neoplasm | tamoxifen | LLT | C1458155 |
| Breast neoplasm | tamoxifen | PT | C1458155 |
| Breast pain | tamoxifen | LLT | C0024902 |
| Breast pain | tamoxifen | PT | C0024902 |
| Bronchitis | tamoxifen | LLT | C0006277 |
| Bronchitis | tamoxifen | PT | C0006277 |
| Cardiovascular disorder | tamoxifen | LLT | C0007222 |
| Cardiovascular disorder | tamoxifen | PT | C0007222 |
| Cataract | tamoxifen | LLT | C0086543 |
| Cataract | tamoxifen | PT | C0086543 |
| Cataract | tamoxifen | PT | C0086543 |
| Cataract specified | tamoxifen | LLT | C0151547 |
| Chest pain | tamoxifen | LLT | C0008031 |
| Chest pain | tamoxifen | PT | C0008031 |
| Cholestasis | tamoxifen | LLT | C0008370 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tamoxifen used for in pharmaceutical contexts?
Tamoxifen (CAS 10540-29-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Tamoxifen?
Tamoxifen has 1,598 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Metastases to bone, Malignant neoplasm progression, Metastases to liver, Metastases to lung, Breast cancer recurrent. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tamoxifen also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Tamoxifen.
What clinical phase is Tamoxifen in?
Tamoxifen is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Tamoxifen?
Tamoxifen has 77 bioactivity rows in this page query. Rendered target entries include Adenosine receptor A1, Sodium/potassium-transporting ATPase subunit alpha-2, Beta-1 adrenergic receptor, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1.